acute ischemic stroke
Conditions
Interventions
A Group:Patients in Group A received standard drug treatment: oral aspirin enteric-coated tablets 100mg once a day
Take atorvastatin calcium tablets 20mg orally once a day. Intravenous infusion of mannitol injection is administered. The specific dosage and frequency are determined by the attending physician based
Intravenous infusion of 100mL of butylphthalide injection twice a day
Take 2.5mg of levamlodipine besylate tablets orally once a day for 14 consecutive days.
B Group:Standard drug treatment (the same as Group A) + Shuangjie Decoction treatment. The composition of the prescription and drug is: 15g of Chinese kale, 15g of Gastrodia elata, 12g of Perilla frut
Sponsors
Weifang Hospital Of Traditional Chinese Medicine
Eligibility
Sex/Gender
All
Age
40 Years to 80 Years
Inclusion criteria
Inclusion criteria: Patients who meet all of the following five criteria can be included in this study: 1) They are diagnosed with acute ischemic stroke according to the Western medical diagnostic criteria and have a National Institutes of Health Stroke Scale (NIHSS) score of 1 to 15, indicating mild to moderate acute ischemic stroke; 2) They are diagnosed with stroke according to the above-mentioned TCM diagnostic criteria and have a score of =7 for the wind syndrome in the TCM syndrome differentiation criteria; 3) Their age is between 40 and 80 years old; 4) The onset time of acute ischemic stroke is less than 48 hours; 5) The patient or their legal representative is willing to participate in the study and can sign the informed consent form.
Exclusion criteria
Exclusion criteria: Patients who met any of the following criteria were excluded from this study: 1) The patient had already suffered from neurological deficits (mRS>2) before the onset of this acute ischemic stroke. 2) The patient is in a coma and has unstable vital signs. 3) The patient requires emergency interventional endovascular thrombectomy or intravenous thrombolysis. 4) Severe heart, lung, liver or kidney insufficiency or other systemic diseases that may affect survival expectations and participation in follow-up; 5) The patient has severe hypertension or diabetes and other diseases. Despite active treatment, the condition has not been effectively controlled (blood pressure persistently >160/100 mmHg, fasting blood glucose persistently >11.1 mmol/L). 6) The researchers believe that other diseases accompanied by the patient may interfere with the correct evaluation of neurological function, or participating in this trial may lead to other complications in the patient. 7) The patient has an allergic constitution and is allergic to the components of the investigational drug and excipients. 8) The patient has participated in other clinical trials within the past 3 months;
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| National Institutes of Health Stroke Scale; | — |
Secondary
| Measure | Time frame |
|---|---|
| Modified Barthel Index;Points of wind syndrome in Traditional Chinese medicine;Hypersensitive C-reactive protein;Central nervous system specific protein;Interleukin- 6;Tumor necrosis factor-a;Homocysteine; | — |
Countries
China
Contacts
Public ContactManli Zhao
Weifang Hospital Of Traditional Chinese Medicine
Outcome results
None listed